secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2022-03-23T23:59:59+00:00
Accession:  0001628280-22-006985
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex provides 2022 outlook: net sales +15-20% YoY; Tru Niagen revenue $56.7M in 2021
--------------------------------------------------------------------------------

- 2021 net sales $67.4M (+14% YoY); Tru Niagen sales $56.7M; gross margin 61.5%.
- 2022 guidance: net sales +15-20% YoY; gross margin ~60%; R&D spend up ~$2M; G&A down $5-6M.
- E-commerce 62% of sales; partnerships expanded with Walmart US and Watsons; new SinoPharm partnership for China.
- Cash $28.2M, zero debt; adjusted EBITDA excl. legal loss $(2.5)M in 2021; litigation expense largely behind.
- Pipeline includes next-gen NAD precursors (NRH, NAR) with 10+ granted patents; 20+ clinical studies supporting NAD+ boosting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828022006985/0001628280-22-006985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828022006985/cdxc-20220323.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-006985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer